Vivos Therapeutics, Inc. (VVOS) has seen a decline of 6.44% and stands at $3.78 in the aftermarket. However, the last trading session concluded at $4.04.
Formation of New Medical Consortium
VVOS announced the formation of a new medical consortium on 23rd September 2021. This physician working group involves experts in sleep medicine, neurology, pediatrics, and pulmonology, etc. It will collaborate to advance Vivos’ OSA technology capabilities. The Vivos Medical Consortium is led by Stanford University’s Clete Kushida and Cecilia Wu of the University of Alberta. It will help the company plan, disseminate, and perform important research projects, improve physician-dental collaborative projects, and broaden novel Vivos advanced technologies for increased medical conditions.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Proper Obstructive Sleep Apnea Diagnosis and Treatment
VVOS announced a new collaborative relationship with Empower Sleep on 26th August 2021. It is a San Bernardino, California-based company that empowers patients with affordable, accessible, and personalized telemedicine sleep care. This can help them provide critical diagnostic and medical counseling services to people suffering from OSA across North America.
Vivos and Empower Sleep want to combine their key technologies to create a user-friendly platform with tailored information for people being evaluated for OSA by dentists and other healthcare practitioners in North America. This partnership is intended to allow more patients than ever before to better understand. This is to interpret how well they are breathing and sleeping at night, as well as the impact sleep has on overall health. As a consequence, patients with any sleep-disordered breathing disorder, including mild to moderate OSA, will be able to get the proper therapy.
FDA Grants 510(k) Market Clearance to VVOS mmRNA Oral Appliance
On 23rd August 2021, VVOS announced that FDA has approved the payment of 510(k) for Vivos’ mmRNA device. Firstly, the FDA approval opens the door to increased insurance reimbursement coverage for the mmRNA device. This includes Medicare, as well as future administration contracts and payment from private payers that follow Medicare rules.
Secondly, sleep apnea affects over 1 billion individuals worldwide, including 54 million Americans, with 80 percent of cases going untreated. Sleep apnea is a significant chronic disorder. Thirdly, it raises the risk of comorbidities such as hypertension, heart failure, stroke, and diabetes, etc. Lastly, patients treated with the Vivos System, unlike current standard-of-care treatments, generally finish their therapy in 12 to 24 months.